Pharma & Biotech

Your team can make content with AI now, but every piece still goes through medical, legal and regulatory review. A reviewer has to put their name on it, and the draft waits while someone gathers comments from email, meetings and the review portal.

The AI budget is approved too, and the plan was to spend it on hiring engineers. Those hires are slow, and the CFO already wants to know what the money has bought.

We start with the handoffs around review and research.

• Copying between systems. Staff move the same claims, references and comments by hand between documents, the review portal and the CRM. Our automation work connects them, so each detail is entered once.
• Review that runs on chasing. Drafts wait while someone pulls comments from email and meetings into one version, then chases the next approval. Our human-in-the-loop work puts each draft in a queue with a named reviewer and a due date, so nobody has to chase it.
• Field insights that get lost. MSLs hear what doctors need every day, and most of it stays buried in CRM notes. Short voice debriefs through our discovery work capture those insights, so medical and commercial teams can act on them.

Content reaches doctors sooner. With review queues, approval logs and named reviewers in the workflow, reviewers spend their time on the calls only they can make, and less of the work goes out to agencies.

Medical and commercial teams see what MSLs hear from doctors each week, in one place. Today that insight sits in CRM notes until someone reads them, often months later.

The CFO sees exactly what the AI budget paid for. We write two or three success measures with you in the first week, and you see numbers from before and after when the first workflow goes live.

Dermsquared is a medical education company that runs the kind of conferences pharma companies sponsor. We built its app and the platform behind it, and Dermsquared owns the code and the data.

Your work looks different, but we'd start the same way: building it into your own tools so your team owns it. There's more in the Dermsquared case study.